OBJECTIVE: The experience with MVAC (methotrexate, vinblastine, Adriamycin and cisplatin) chemotherapy in advanced urothelial cancer is reviewed with emphasis on toxicity and efficacy. METHODS: We report on 28 patients with advanced, progressive transitional cell carcinoma (TCC) of the bladder (27) or ureter (1), treated with MVAC. RESULTS: The average number of cycles was 4.5. Leucopenia was the most frequent and severe side effect (18% WHO grade I, 46% GII, 19% GII and 4% GIV). Other side effects were acceptable and could be treated successfully. One patient (complete responder) died of a toxic cause (sepsis), a second patient (partial responder) died of an intestinal bleeding (not drug- or cancer-related). Complete response was seen in 10 patients (36%), partial response and stable disease in 4 patients each (14%), progression in 8 patients (29%), and 2 patients were not evaluable for response. However, relapses were frequent (8 of 12 remaining responders, 66%). Median survival of the whole group was 9 months (0-52), without a significant difference for responders and nonresponders (p = 0.29). CONCLUSION: Our results are comparable to data from the literature with regard to efficacy and toxicity, although detailed toxicity data are unfortunately not always available.
OBJECTIVE: The experience with MVAC (methotrexate, vinblastine, Adriamycin and cisplatin) chemotherapy in advanced urothelial cancer is reviewed with emphasis on toxicity and efficacy. METHODS: We report on 28 patients with advanced, progressive transitional cell carcinoma (TCC) of the bladder (27) or ureter (1), treated with MVAC. RESULTS: The average number of cycles was 4.5. Leucopenia was the most frequent and severe side effect (18% WHO grade I, 46% GII, 19% GII and 4% GIV). Other side effects were acceptable and could be treated successfully. One patient (complete responder) died of a toxic cause (sepsis), a second patient (partial responder) died of an intestinal bleeding (not drug- or cancer-related). Complete response was seen in 10 patients (36%), partial response and stable disease in 4 patients each (14%), progression in 8 patients (29%), and 2 patients were not evaluable for response. However, relapses were frequent (8 of 12 remaining responders, 66%). Median survival of the whole group was 9 months (0-52), without a significant difference for responders and nonresponders (p = 0.29). CONCLUSION: Our results are comparable to data from the literature with regard to efficacy and toxicity, although detailed toxicity data are unfortunately not always available.
Authors: Kenny H Cha; Lubomir M Hadjiiski; Richard H Cohan; Heang-Ping Chan; Elaine M Caoili; Matthew S Davenport; Ravi K Samala; Alon Z Weizer; Ajjai Alva; Galina Kirova-Nedyalkova; Kimberly Shampain; Nathaniel Meyer; Daniel Barkmeier; Sean Woolen; Prasad R Shankar; Isaac R Francis; Phillip Palmbos Journal: Acad Radiol Date: 2018-11-10 Impact factor: 3.173
Authors: Kenny H Cha; Lubomir M Hadjiiski; Ravi K Samala; Heang-Ping Chan; Richard H Cohan; Elaine M Caoili; Chintana Paramagul; Ajjai Alva; Alon Z Weizer Journal: Tomography Date: 2016-12
Authors: Eric Wu; Lubomir M Hadjiiski; Ravi K Samala; Heang-Ping Chan; Kenny H Cha; Caleb Richter; Richard H Cohan; Elaine M Caoili; Chintana Paramagul; Ajjai Alva; Alon Z Weizer Journal: Tomography Date: 2019-03
Authors: Di Sun; Lubomir Hadjiiski; Ajjai Alva; Yousef Zakharia; Monika Joshi; Heang-Ping Chan; Rohan Garje; Lauren Pomerantz; Dean Elhag; Richard H Cohan; Elaine M Caoili; Wesley T Kerr; Kenny H Cha; Galina Kirova-Nedyalkova; Matthew S Davenport; Prasad R Shankar; Isaac R Francis; Kimberly Shampain; Nathaniel Meyer; Daniel Barkmeier; Sean Woolen; Phillip L Palmbos; Alon Z Weizer; Ravi K Samala; Chuan Zhou; Martha Matuszak Journal: Tomography Date: 2022-03-02
Authors: Lubomir M Hadjiiski; Kenny H Cha; Richard H Cohan; Heang-Ping Chan; Elaine M Caoili; Matthew S Davenport; Ravi K Samala; Alon Z Weizer; Ajjai Alva; Galina Kirova-Nedyalkova; Kimberly Shampain; Nathaniel Meyer; Daniel Barkmeier; Sean A Woolen; Prasad R Shankar; Isaac R Francis; Phillip L Palmbos Journal: Tomography Date: 2020-06